OARSI Imaging Discussion Group – Program World Congress Seoul 2025

Regulatory Aspects and Imaging Biomarker Qualification Update

Saturday, April 26, 2025, Incheon, Korea 12:30-2:00 pm Songdo Convensia, Room 206/207

Lunch will be sponsored Chondrometrics GmbH, Freilassing, Germany https://www.chondrometrics.com

12:30-12:35 pm - Introduction (Thomas M. Link, MD, PhD)

12:35-12:45 pm - Recent Insights into Disease Modifying Trials

Speaker: **Felix Eckstein, MD** (Professor, Research Group for Musculoskeletal Imaging, Center for Anatomy and Cell Biology, Paracelsus Medical University, Salzburg, Austria; Chief Executive Officer & Medical Officer, Chondrometrics GmbH, Freilassing, Germany)

12:45-12:55 pm – Regulatory Aspects of Disease Modifying Trials Speaker: Asger Reinstrup Bihlet, MSc, PhD (Chief Scientific Officer, NBCD, Sanos Group, Sobora, Denmark)

12:55-1:05 pm — Biomarker Qualification Update with a Focus on Disease Modifying Trials

Speaker: David Hunter MBBS, MSc (Clin Epi), M SpMed, PhD, FRACP (Rheum), (Florance and Cope Chair of Rheumatology, Professor of Medicine, Osteoarthritis Clinical Research Group, Kolling Institute, Arabanoo Precinct, Sydney Musculoskeletal Health, Faculty of Medicine and Health, The University of Sydney; Co-Editor in Chief of Osteoarthritis and Cartilage)

1:05-1:55 - **Panel discussion** – Regulatory Aspects of Imaging Biomarkers in the Era of Artificial Intelligence moderated by *Flavia Cicuttini, MD and Frank Roemer, MD*

1:55-2:00 Summary and wrap up (Frank Roemer, MD)

Co-Chairs and Committee Members:

Xiaojuan Li (Cleveland Clinics), Thomas M. Link (UCSF),

Flavia Cicuttini (Monash University and Rheumatology, Alfred Hospital), Mylene Jansen (University of Utrecht), Frank Roemer (University of Erlangen-Nuremberg), Felix Eckstein (Paracelsus Medical University, Chondrometrics GmbH) and Tom Turmezei (Norfolk and Norwich University Hospital)